Butterfly Network hires Chirp co-founder to lead chip licensing By Investing.com

Q4 revenue was $31.5M (+41% YoY), beating forecasts by ~22.9%, and EPS loss narrowed to $0.02 vs an expected $0.05. Butterfly appointed David Horsley to lead its Butterfly Embedded licensing/co-development initiative as embedded revenue (including $6.8M from Midjourney) helps drive growth; LTM revenue rose ~19% and the stock is up 151% over six months with a market value of ~$957M. Analysts expect ~21% revenue growth for fiscal 2026 and Freedom Capital Markets raised its price target from $5.00 to $5.50 (Buy), though the company remains unprofitable and trades above fair value.

Analysis

A shift from selling end-point medical devices toward licensing semiconductor/IP fundamentally changes unit economics and go-to-market cadence. Licensing lifts gross-margin potential (think tens of points vs device hardware) but substitutes steady product sales with binary design-win and royalty cliffs; material revenue inflection typically arrives only after 9–18 month partner design cycles and then shows up as lumpy, back-loaded ARR.

Second-order winners are not incumbent OEMs but foundries, ASIC design houses, and systems integrators that shorten partner time-to-market; constrained specialty MEMS/PMUT capacity or a single manufacturing partner creates asymmetric execution risk and can bottleneck scaling within a 3–9 month window. Conversely, traditional med-tech competitors that own channel/reimbursement relationships retain advantage for hospital diagnostic use — embedded semiconductor players must either accept lower-cost consumer/enterprise use-cases or invest years and expense to clear clinical regulatory pathways.

Key tail-risks are execution and classification: missed design-wins, delays in partner certifications, or a reclassification of embedded features as regulated diagnostics can compress valuation rapidly. Near-term catalysts to watch are (1) concrete multi-customer licensing terms or royalty schedules, (2) public disclosure of multi-year supply agreements with fabs, and (3) sequential share of revenue from licensing vs devices; any of these moving unfavorably can flip sentiment within 30–90 days.

From a valuation perspective the market is pricing a path to high-margin recurring revenue; that’s valid only if a handful of Tier-1 OEMs convert pilots into production. The trade is therefore binary and best expressed with structures that pay off if one or two large partners prove out while limiting downside if they don’t.

Key Decisions for Investors

• Long structured call spread on BFLY (6–9 month): buy-to-open a 6–9 month ATM call and sell a higher strike to fund cost (target 2:1 upside if design-win cadence accelerates). R/R: limited premium risk (define max loss = premium), upside capped but >100% if market re-rates after partner commercialization. Exit on two consecutive quarters showing licensing >20% of revenue or a 30% adverse move.
• Protective collar for existing BFLY equity positions (3 months): buy 10–15% OTM puts and sell calls 20–30% above current price to limit downside to ~20–25% net cost. Use this if retention of upside optionality is desired while guarding against binary partner disappointment within the next 90 days.
• Relative-value pair (3–9 months): long SMCI vs short BFLY, equal notional. Rationale: prefer durable hardware/server fundamentals and clearer cash generation over binary licensing bets. Target relative outperformance of 15–30%; stop-loss if pair moves against you by 12% in 2 weeks.
• Event-driven short/credit spread on BFLY (90–180 days): if expected partner announcements or reported embedded revenue miss internal milestones, initiate bearish put credit spread to capture constrained upside and time decay. Size small (<=3% portfolio) and set stop at 25% adverse move — this hedges the risk of re-rating when lumpy licensing falls short.